À retenir
Pooling 12 papers, a low-FODMAP diet lowered irritable bowel syndrome severity more than control diets (standardized mean difference -0.66, 95% CI -0.88 to -0.44) and raised quality-of-life scores. The trials were few and varied in design, and the abstract leaves long-term nutrition and gut-microbiome effects unanswered.
Study design
Revue des preuves
Reading basis
Published abstract
Reading focus
Design & applicability
Cette explication éditoriale existe en anglais, chinois simplifié et chinois traditionnel. Cette interface affiche la lecture en anglais.
Question de recherche
The low-FODMAP diet restricts fermentable carbohydrates that can provoke gut symptoms, but it is demanding to follow and cuts many foods. The authors updated the evidence on whether it eases symptoms and quality of life in adults with irritable bowel syndrome (IBS), and what it does to nutritional adequacy and the gut microbiome.
Population et méthode
Systematic review and meta-analysis. The authors searched the literature up to October 2020 for observational and intervention studies of low-FODMAP diets in IBS patients. Twelve papers (nine parallel trials, three crossover studies) entered the meta-analysis. Symptom severity was expressed as standardized mean differences, IBS quality of life (IBS-QoL) as mean differences, using random-effects models with inverse-variance weighting. The review was registered as PROSPERO CRD42020175157. The abstract does not give participant numbers.
Résultats
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Symptom severity fell by a moderate-to-large amount on the low-FODMAP diet compared with a control diet: standardized mean difference -0.66 (95% CI -0.88 to -0.44), with moderate heterogeneity (I2 = 54%).
- 2In studies using the validated IBS Severity Scoring System (IBS-SSS) questionnaire, the average reduction was 45 points (95% CI -77 to -14), but heterogeneity was high (I2 = 89%), so the size of benefit differed a lot between studies.
- 3IBS-QoL scores rose by 4.93 points more than with the control diet (95% CI 1.77 to 8.08; I2 = 42%).
- 4Subgroups split by adherence, age, intervention duration, IBS subtype, outcome measure and risk of bias showed no significantly different results.
Limites et incertitude
- 1Only 12 papers were pooled, and the abstract does not say how many people they included, so the pooled estimates may be fragile.
- 2Heterogeneity was high (I2 = 89%) for the IBS-SSS analysis, meaning the 45-point average hides large differences between studies.
- 3The authors say long-term effects on nutritional adequacy and the gut microbiome remain unanswered, so safety of staying on the diet is unclear.
- 4This reading is based on the abstract only.
Mise en perspective
For adults with diagnosed IBS, the pooled data support the low-FODMAP diet as a way to reduce symptoms over the short term. It restricts many foods, so starting it, and reintroducing foods afterward, is best done with a clinician or dietitian. These results do not show that people without IBS benefit.
Vos données
If you and your clinician try this diet, a daily symptom and food log is the most useful record. Compare weeks on the diet with your own earlier baseline, not with other people, and note stress and sleep that may also shift symptoms.
Comprendre ce type de preuve
Check which designs were included, how searches and bias assessment were conducted, and the last search date. Publication date alone does not make the underlying evidence current.
Résumé structuré des auteurs English
Le résumé original en anglais est reproduit avec attribution sous la licence ouverte indiquée. Il s’agit d’une source, pas d’une interprétation MoveVitals. L’analyse préparée figure ci-dessus ; vérifiez les conclusions importantes dans la source.
Purpose
This review provides an updated overview of observational and intervention studies investigating the effect of a low-FODMAP (fermentable oligo-, di- and monosaccharides, and polyols) diet (LFD) on gastrointestinal (GI) symptoms, quality of life (QoL), nutritional adequacy, and gut microbiome in irritable bowel syndrome (IBS) patients.
Methods
We systematically searched available literature until October 2020 for studies that investigated the effect of LFDs on GI symptoms, QoL, nutritional adequacy, and the gut microbiome in IBS patients. The data were represented as standardized mean differences (SMD) for IBS severity, and as mean differences (MD) for IBS-QoL. Meta-analyses were performed for the quantitative analyses using random effects models with inverse variance weighing.
Results
Twelve papers (nine parallel trials, three crossover studies) were included for the meta-analysis. The LFD reduced IBS severity by a moderate-to-large extent as compared to a control diet (SMD - 0.66, 95% CI - 0.88, - 0.44, I^(2) = 54%). When analyzing only studies that used the validated IBS-SSS questionnaire, a mean reduction of 45 points (95% CI - 77, - 14; I^(2) = 89%) was observed. Subgroup analyses on adherence, age, intervention duration, IBS subtype, outcome measure, and risk of bias revealed no significantly different results. The LFD also increased IBS-QoL scores, when compared with a control diet (MD 4.93; 95% CI 1.77, 8.08; I^(2) = 42%).
Conclusions
The low-FODMAP diet reduces GI symptoms and improves quality of life in IBS subjects as compared to control diets. Future work is required to obtain definitive answers regarding potential long-term effects of such diets on nutritional adequacy and the gut microbiome.
Prospero registration number
CRD42020175157.
Sources et attribution
Efficacy of a low-FODMAP diet in adult irritable bowel syndrome: a systematic review and meta-analysis.
van Lanen AS, de Bree A, Greyling A.
European journal of nutrition · 2021-02-14
DOI: 10.1007/s00394-020-02473-0 ↗PubMed · 33585949 ↗Europe PMC · Licence indiquée: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
Interprétation éditoriale MoveVitals · contenu éducatif · aucune évaluation clinique individuelle enregistrée
Sources vérifiées 2026-11-01
Guides pratiques
À lire ensemble
Early time-restricted eating linked to more weight loss and lower insulin than late eating
Pooling 41 randomised trials (2287 participants, median intervention 8 weeks), time-restricted eating was associated with 2.15 kg lower body weight than usual diets (95% CI -2.56 to -1.74), and eating early beat eating late by 1.15 kg (95% CI -1.86 to -0.45). Most trials were short, only 6 study arms tested early eating, and the outcomes were body and blood measures, not heart attacks or deaths.
BMJ Medicine
An 8 a.m. to 4 p.m. eating window added to calorie cutting gave no clear extra weight loss
Among 139 patients with obesity on a calorie-restricted diet, adding an eating window of 8:00 a.m. to 4:00 p.m. led to a mean 12-month weight change of -8.0 kg, versus -6.3 kg with calorie restriction alone. The net difference of -1.8 kg (95% CI -4.0 to 0.4; P = 0.11) was not statistically significant, and the interval cannot rule out either a real benefit or none.
The New England Journal of Medicine
In a 20-person ward trial, an ultra-processed menu led to more eating and weight gain
In 20 adults living in a hospital research unit for 28 days, an ultra-processed menu led them to eat 508 kcal/day more (± 106 SE, P = 0.0001) and gain 0.9 kg, while a menu of unprocessed foods led to a 0.9 kg loss, each over 2 weeks and with eating left to appetite. The study was small, short and fully provisioned, so it cannot show what happens in daily life or which feature of the foods drove the extra eating.
Cell Metabolism
Mediterranean diet with olive oil or nuts linked to fewer heart events (corrected trial)
Among 7447 Spanish adults aged 55 to 80 at high cardiovascular risk, those assigned to a Mediterranean diet with extra-virgin olive oil (HR 0.69, 95% CI 0.53 to 0.91) or with nuts (HR 0.72, 0.54 to 0.95) had fewer major cardiovascular events than those told to cut dietary fat. The trial had randomisation errors, which is why the 2013 report was withdrawn and the estimates recalculated, so treat this as strong but imperfect evidence.
The New England Journal of Medicine

